Ally Bridge Group logo

Ally Bridge Group

Asia, Hong Kong Island, Hong Kong, Hong Kong

Description

Ally Bridge Group is a healthcare-focused investment group committed to venture and growth capital, buyout, and hedge fund investing.

Investor Profile

Ally Bridge Group has made 90 investments, with 16 in the past 12 months and 40% as lead.

Stage Focus

  • Post Ipo Equity (22%)
  • Series D (14%)
  • Series B (14%)
  • Series C (13%)
  • Series Unknown (9%)
  • Private Equity (8%)
  • Series E (7%)
  • Series A (6%)
  • Series G (2%)
  • Series F (2%)

Country Focus

  • United States (81%)
  • China (7%)
  • Canada (4%)
  • Ireland (2%)
  • United Kingdom (2%)
  • Singapore (1%)
  • Israel (1%)
  • France (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Medical Device
  • Pharmaceutical
  • Biopharma
  • Oncology
  • Life Science
  • Health Diagnostics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ally Bridge Group frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 16
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 8
Avidity Partners
North America, Texas, United States, Dallas
Co-Investments: 9
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 13
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 8
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 13
Rock Springs Capital
North America, Maryland, United States, Baltimore
Co-Investments: 11
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 16
Venrock
North America, California, United States, Palo Alto
Co-Investments: 9
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 11

Which angels does Ally Bridge Group often collaborate with?

Daphne Teo
Asia, Singapore
Shared Deals: 1
SH
North America, California, United States, Santa Monica
Shared Deals: 1

What are some of recent deals done by Ally Bridge Group?

Epicrispr Biotechnologies

South San Francisco, California, United States

Epic Bio's strength is a relentless focus on ushering in a new era of gene regulation.

BiotechnologyHealth Care
Series BMar 26, 2025
Amount Raised: $68,000,000
Cardiac Dimensions

Kirkland, Washington, United States

Cardiac Dimensions is a medical device company developing tools and techniques for the treatment of heart failure and related conditions.

BiotechnologyHealth CareMedical Device
Series EMar 20, 2025
Amount Raised: $53,000,000
Arbor Biotechnologies

Cambridge, Massachusetts, United States

Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.

BiopharmaBiotechnologyLife Science
Series CMar 18, 2025
Amount Raised: $73,900,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityMar 4, 2025
Amount Raised: $100,000,000
VitalConnect

San Jose, California, United States

VitalConnect offers wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations.

BiotechnologyHealth CareMedical DeviceWearables
Series UnknownFeb 19, 2025
Amount Raised: $100,000,000
Tectonic Therapeutic

Allston, Massachusetts, United States

Tectonic Therapeutic is a biotechnology company which focuses on scientific research in biochemistry and molecular pharmacology.

Biotechnology
Post Ipo EquityFeb 3, 2025
Amount Raised: $185,000,000
Aerin Medical

Mountain View, California, United States

Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing.

BiotechnologyHealth CareMedical DeviceTherapeutics
Private EquityJan 13, 2025
Amount Raised: $32,500,000
Aadi Bioscience

Pacific Palisades, California, United States

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

BiopharmaBiotechnologyLife ScienceOncology
Post Ipo EquityDec 20, 2024
Amount Raised: $100,000,000
ProMIS Neurosciences

Toronto, Ontario, Canada

ProMIS Neurosciences develops therapeutic products and diagnostic devices targeting misfolded protein diseases.

BiotechnologyHealth DiagnosticsMedicalNeuroscienceTherapeutics
Post Ipo EquityJul 26, 2024
Amount Raised: $30,300,000
Imperative Care

Campbell, California, United States

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health CareMedicalMedical Device
Series EJul 25, 2024
Amount Raised: $150,000,000